Occurrence of cold activation of transfusion plasma during storage at +4 °C

Vox Sanguinis

Volumn 88, Issue 3, 2005, Pages 172-180

  Suontaka, Anna Maija ^a   Silveira, A ^a   Soderstrom T ^a   Blomback M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coagulation system; Cold activation; Contact system; Fibrinolytic system; Plasma storage

Indexed keywords

BLOOD CLOTTING FACTOR 7; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOPEPTIDE A; KALLIKREIN; PLASMIN INHIBITOR; PLASMINOGEN;

APHERESIS; ARTICLE; BLOOD CLOTTING; BLOOD STORAGE; FIBRINOLYSIS; HUMAN; HUMAN CELL; MALE; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD TRANSFUSION; COLD; COMPLEMENT C1S; ENZYME INHIBITORS; FACTOR VIIA; FIBRINOPEPTIDE A; HUMANS; PLASMA; PLASMIN; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS;

EID: 17144418600     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2005.00617.x     Document Type: Article

References (32)

1. Nilsson L, Hedner U, Nilsson IM, Robertson B: Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion 1983; 23:377-381
2. Suontaka AM, Bremme K, Åkerblom O, Blombäck M: Blood component processing technique and plasma quality. Infusionsther Transfusionsmed 1992; 19:110-114
3. Blombäck M, Chmielewska J, Netré C, Åkerblom O: Activation of blood coagulation, fibrinolytic and kallikrein systems during storage of plasma. Vox Sang 1984; 47:335-342
4. Gjønnæss H: Cold promoted activation of factor VII. II. Identification of the activator. Thrombos Diathes Haemorrh 1972; 28:169-181
5. Gjønnæss H: Cold promoted activation of factor VII. Occurrence and relation to sex hormones and antifertility compounds. Gynecol Invest 1973; 4:61-72
6. Seligsohn U, Østerud B, Rapaport SI: Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52:978-988
7. Seligsohn U, Zivelin A, Bar-Shani S: Cold-promoted activation of factor VII. Is it a problem under blood bank conditions? Haemostasis 1983; 13:186-191
8. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744
9. Colman RW: Contact activation pathway: inflammatory, fibrinolyrjc, anticoagulant, antiadhesive, and antiangiogenic activities; in Colman RW, Hirsch J, Marder VJ, Clowes AW, George JN (eds): Hemostasis and Thrombosis. Basic Principles and Clinical Practice, edn 4. Philadelphia, Lippincott Williams & Wilkins, 2001:103-121
10. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, Finlayson JS: Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med 1978; 299:66-70
11. Alving BM, Tankersley DL, Mason BL, Rossi F, Aronson DL, Finlayson JS: Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-346
12. Shiba M, Tadokoro K, Sawanobori M, Nakajima K, Suzuki K, Juji T: Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997; 37:457-462
13. Hild M, Söderström T, Egberg N, Lundahl J: Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrations. Vox Sang 1998; 75:18-25
14. Fried MR, Eastlund T, Christie B, Mullin GT, Key NS: Hypotensive reactions to white cell reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion 1996; 36:900-903
15. Hume HA, Popovsky MA, Benson K, Glassman AB, Hines D, Oberman HA, Pisciotto PT, Anderson KC: Hypertensive reactions: a previously uncharacterized complication of platelet transfusion? Transfusion 1996; 36:904-909
16. Gallimore MJ, Friberger P: Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein 'like' activity in human plasma. Thromb Res 1982; 25:293-298
17. Kleindel M, Lang H, Philapitsch A, Wöber G: A rapid method for determination of C1-esterase activity using a new chromogenic substrate. Thromb Haemost 1983; 50:244
18. Amiral J, Walenga JM, Fareed J: Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost 1984; 10:228-242
19. Gram J, Jespersen J: A functional plasminogen assay utilizing the potential effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost 1985; 53:255-259
20. Billing Clason S, Meijer P, Kluft C, Ersdal E: Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures. Blood Coagul Fibrinol 1999; 10:487-494
21. Smith JK: Quality of plasma for fractionation - does it matter? Transfus Sci 1994; 15:343-350
22. Weiss R, Silverberg M, Kaplan AP: The effect of C1 inhibitor upon Hageman factor autoactivation. Blood 1986; 68:239-243
23. 2-macroglobulin-kallikrein complexes. J Biol Chem 1985; 260:4257-4263
24. España F, Estelles A, Griffin JH, Aznar J: Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma. Thromb Haemost 1991; 65:46-51
25. Radcliffe R, Bagdasarian A, Colman R, Nemerson Y: Activation of bovine factor VII by Hageman factor fragments. Blood 1977; 50:611-617
26. Radcliffe R, Nemerson Y: Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975; 250:388-395
27. Radcliffe R, Nemerson Y: Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa. J Biol Chem 1976; 251:4797-4802
28. Qureshi GD, Nossel HL: Stability studies of human fibrino-peptide A as measured by radioimmunoassay. Proc Soc Exp Biol Med 1972; 140:1069-1072
29. Teger-Nilsson AC: Degradation of human fibrinopeptides A and B in blood serum in vitro. Acta Chem Scand 1968; 22:3171-3182
30. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP: Mechanism of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71:1450-1456
31. DiScipio RG: The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45:587-595
32. 125I-labeled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett 1979; 97:111-115